A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma

• Type of Material: Article
• Authors: Abeer N. AbouYabis, Mercer University; Pareen J. Shenoy, Emory University; Rajini Sinha, Emory University; Christopher R Flowers, Emory University; Mary Jo Lechowicz, Emory University
• Language: English
• Date: 2011-04-20
• Publisher: Hindawi Publishing Corporation
• Publication Version: Final Published Version
• Copyright Statement: © 2011 Abeer N. AbouYabis et al.
• License: Creative Commons Attribution 3.0 Unported
• Final Published Version (URL): http://www.hindawi.com/isrn/hematology/2011/623924/
• Title of Journal or Parent Work: ISRN Hematology
• ISSN: 2090-441X
• Volume: 2011
• Issue: 2011
• Start Page: 1
• End Page: 14
• Grant/Funding Information: This work has been supported by Dr. C. R. Flowers’ Georgia Cancer Coalition Distinguished Scientist Award and the American Society of Hematology Amos Medical Faculty Development Award.
• Research Categories: Health Sciences, Oncology

Abstract

Anthracycline-based chemotherapy remains standard treatment for peripheral T-cell lymphoma (PTCL) although its benefits have been questioned. We performed systematic literature review and meta-analyses examining the complete response (CR) and overall survival (OS) rates for patients with PTCL. The CR rate for PTCL patients ranged from 35.9% (95% CI 23.4–50.7%) for enteropathy-type T-cell lymphoma (ETTL) to 65.8% (95% CI 54.0–75.9%) for anaplastic large cell lymphoma (ALCL). The 5-year OS was 38.5% (95% CI 35.5–41.6%) for all PTCL patients and ranged from 20.3% (95% CI 12.5–31.2%) for ETTL to 56.5% (95% CI 42.8–69.2%) for ALCL. These data suggest that there is marked heterogeneity across PTCL subtypes in the benefits of anthracycline-based chemotherapy. While anthracyclines produce CR in half of PTCL patients, this yields reasonable 5-year OS for patients with ALCL but not for those with PTCL-NOS or ETTL. Novel agents and regimens are needed to improve outcomes for these patients.